Trial Profile
Phase II study of Upamostat in Chinese patients with solid tumour
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 27 Mar 2019 New trial record
- 21 Mar 2019 According to a Heidelberg Pharma AG media release, due to changes in the trial regulations of the Chinese regulatory authority, there is now a chance that a Phase II trial can begin immediately based on earlier data from the USA and Europe.